Amy Moore, Vice President of Global Engagement and Patient Partnerships at LUNGevity Foundation, recently shared a post by Chul Kim, Thoracic Medical Oncologist at Georgetown University, on X, adding:

“As targeted therapy moves to the early-stage setting in lung cancer, it is imperative: first to improve early detection to find those who will benefit and second to conduct comprehensive biomarker testing to match people to the appropriate treatment.”

Quoting Chul Kim’s post:

“Check out our article featured in ASCO Daily News ‘Improving Outcomes for Early-Stage NSCLC Using Targeted Therapy.’

A big shout-out to Dr. Vanya Aggarwal, a second-year fellow at Georgetown Lombardi, for her great work”

Read further.
Sources: Amy Moore/X and Chul Kim/X